LAS VEGAS — Abuse-deterrent extended-release oxycodone (Xtampza® ER; Collegium Pharmaceutical) provided adequate pain relief for patients with chronic low back pain who were previously receiving immediate-release oxycodone, according to research presented at PAINWeek 2017, held September 5-9, in Las Vegas, Nevada.1
In a post hoc analysis of a phase 3 efficacy and safety study of the abuse-deterrent oxycodone ER, researchers evaluated the impact of switching from immediate-release oxycodone to extended-release oxycodone over a 12-week period. All participants had chronic low back pain that was poorly managed on an immediate-release oxycodone regimen.
At week 12, patients had significant improvements in average pain intensity from baseline (mean difference [SE]: -1.94 [0.62]; P =.002). The oxycodone extended-release group also had significantly better global impressions of change, a smaller proportion of study drop-out, and different responder analysis compared with placebo (P <.005 for all). Patients receiving oxycodone extended-release also used numerically less rescue medication. Adverse events did not differ between groups in this study.
In an interview with Clinical Pain Advisor, Diana Meske, PhD, lead author on the study, said that the data “support that some patients on an immediate-release oxycodone regimen can be switched to a dose of Xtampza ER to effectively and safely control their pain.”
Disclosure: Dr Meske reports being employed by Collegium Pharmaceutical.
- Meske D, Place A, Vaughn B. Converting patients with chronic pain from immediate-release oxycodone to Xtampza® ER, an extended-release, abuse-deterrent formulation. Presented at: PAINWeek 2017; September 5-9; Las Vegas, Nevada. Abstract 18.